RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408)
ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract
surgery.